“What vaccine strategy in the face of variants?“This is the question posed by High Authority of Health in a press release posted on April 9. In particular, the South African variant, resistant to the AstraZeneca vaccine, imposes new vaccination guidelines.
For HAS, this vaccine should therefore not be used in areas where this variant circulates a lot.
Pfizer and Moderna for Guyana, Mayotte and Reunion
Which territories are we talking about? Overseas first, mainly Guyana, Mayotte, and Reunion, where the South African variant represents between 40 and 48% of cases.
In these departments, “HAS recommends the continuation of the strategy already in place with the exclusive use of messenger RNA vaccines “, namely Pfizer and Moderna.
Read also: People under 55 who have received a dose of AstraZeneca will have a second dose of Pfizer or Moderna
Pfizer, Moderna and Janssen in Moselle
In mainland France, the Moselle is also concerned. The South African variant is there “significantly present“, since it represents 35% of cases.
Even if its prevalence does not seem to be increasing, the HAS recommends “continue to prioritize access to vaccines for which data are available to maintain a high level of efficacy against the South African variant“These are the Pfizer and Moderna vaccines but also the Janssen vaccine, which should arrive in France from April 19.
Janssen is not currently recommended for overseas departments, “where the supply of a single type of vaccine is favored by logistical constraints“explains HAS.
AstraZeneca effective against the English variant
What about the other departments? “The proportion of the South African variant remains systematically below 20%“reassures the health authority. That”does not justify setting up, at this stage, a differentiated strategy for the use of vaccines“.
Indeed, the scientific data available to date suggests that the four vaccines authorized in France – Pfizer, Moderna, AstraZeneca and Janssen – “remain active against the English variant“, currently majority variation in France, notes the HAS.